Please Wait a Moment
X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

27 Jul, 2020 | Return|

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

Reminder- Check flights and cargo hours for the Christmas Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

FDA Guidance ZIKV Testing Strategy Webinar

On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...

Read More >

FDA announces withdrawal of Guidance for ZIKV Testing

We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...

Read More >

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >

Reminder- Check flights and cargo hours for the Christmas Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

Exhibiting at AABB Annual Meeting- Booth 1038

We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...

Read More >